Overview

Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for Duchenne muscular dystrophy and other rare diseases. The lead clinical asset is HT-100, and drug candidate with potent anti-inflammatory and anti-fibrotic properties that also promotes healthy muscle regeneration. The company's second clinical candidate is DT-200, a Selective Androgen Receptor Modulator (SARM), targeted to build muscle mass and strength. Akashi is a combination of Halo Therapeutics and Dart Therapeutics, two companies founded as a collaboration between patient advocacy organizations and biotechnology industry veterans. Akashi is lead by a team of experienced drug developers.